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Head and neck cancer is a major cause of morbidity and
mortality worldwide. The most common cancer in the head
and neck area is head and neck squamous cell carcinoma
(HNSCC) which is the 6th most common cause of can-
cer worldwide. Thyroid cancer accounts for approximately
37000 new cases per year in the United States and 1,600
deaths. The purpose of this special issue is to provide an
update on recent advances in the understanding of head
and neck tumorigenesis and their implications in clinical
practice.
The most extensively studied pathway for targeted ther-
apy in HNSCC is the Epidermal Growth Factor Receptor
(EGFR) pathway. The EGFR-directed monoclonal antibody,
cetuximab, is FDA- and EMA-approved for the treatment
of HNSCC. Although the vast majority of HNSCCs contain
highEGFRlevels,clinicalresponsestoEGFR-targetingthera-
pieshavebeenthemodest.Molecularpredictorsforresponse
to EGFR-targeted therapies in HNSCC are needed. The
review by Egloﬀ et al. provides a comprehensive and updated
overview of candidate predictive markers in response to
EGFR-targeted therapies in HNSCC including Src family
kinases and describes recent clinical trials combining Src-
and EGFR-targeted therapeutics. Fountzilas et al. analyzed
retrospectively 37 patients with locally advanced HNSCC
treated with concomitant radiotherapy, weekly cisplatin, and
cetuximab for a series of biomarkers (tumor EGFR, MET,
ERCC1, and p-53 protein and/or gene expression, MMP9
mRNA) and correlated those with treatment response.
MMP9 was the only biomarker tested that appears to be of
predictive value in cetuximab-treated patients. Validation of
this ﬁnding in large independent cohorts is needed before its
clinical implementation.
Molecular classiﬁcation is a very important research
area since the traditional clinical-pathological factors do
not provide accurate prognostic information. The review
by Ferrari et al. provides a comprehensive overview of the
immunohistochemical expression of biomolecular mark-
ers in tongue cancer and their relationships with clinical
behavior and prognosis. Pentheroudakis et al. evaluated the
prognostic signiﬁcance of mRNA levels of the EGFR family
members HER1-4, the Vascular Endothelial Growth Factors
(VEGFs) A, B, C, D, and their receptors VEGFR1, 2, 3
in a small retrospective cohort of HNSCC. The authors
reported that high expression of the VEGF-C/VEGFR3 axis
in recurrent HNSCC is associated with neck failure (soft
tissues/lymph nodes) and inferior survival postrelapse but
these ﬁndings need to be conﬁrmed in large cohorts.
In addition to EGFR pathway, major research eﬀorts
concentrate on the identiﬁcation of other targets for therapy
in HNSCC. Akt expression and hyperactivation is a fre-
quent event in HNSCC and strongly correlates with disease
progression. Simons et al. explored the hypothesis that the
Akt inhibitor, perifosine (PER), combined with inhibitors
of glutathione (GSH) and thioredoxin (Trx) metabolism
induces cytotoxicity via metabolic oxidative stress in human
head and neck cancer (HNSCC) cells. The authors showed
that PER induces oxidative stress and clonogenic killing in
HNSCC cell lines that is potentiated with inhibitors of GSH
and Trx metabolism. These data provide a biochemical ratio-
nale for the use of inhibitors of GSH and Trx metabolism2 Journal of Oncology
in combination with PER in combined modality cancer
therapies.
Nuclear receptors are implicated in carcinogenesis.
Knauer et al. summarize the function, prognostic/ther
apeutic value, and, most importantly, ongoing preclinical
and clinical studies targeting nuclear receptors in HNSCC.
Several lines of evidence support the existence of cancer
stem cell subpopulation in solid tumors, including HNSCC.
These stem cells account for tumor resistance and aggressive
behavior. Chen et al. introduce us to the stem cell concept
in HNSCC and its potential application in the treatment
of HNSCC patients. The eukaryotic translation initiation
factor eIF4E is upregulated in approximately 30% of human
cancers including HNSCC and this upregulation correlates
with poor prognosis in HNSCC. Culjkovic et al. present
the biochemical and molecular properties of the oncogenic
potential of eIF4E, the potential strategies for eIF4E tar-
geting in the clinic, and their utility in HNSCC patients.
Immunotherapy has been used with limited eﬃcacy in
several solid tumors including HNSCC. The comprehensive
and updated review by Rapidis et al. summarizes the
rationale for immunotherapy in HNSCC and the principal
approaches under investigation.
Advances in radiotherapy promise to increase cure rates
and reduce acute and late morbidity of patients with
HNSCC. Nath et al. provide a detailed overview of image-
guided radiotherapy in head and neck cancer patients as
well as clinical studies analyzing its use in target delineation,
patient positioning, and adaptive radiotherapy.
Accurate staging of HNSCC is essential for developing
therapeutic strategies in patients with HNSCC. Al-Ibraheem
et al. provide an updated summary on 18F-FDG PET
and PET/CT imaging of head and neck cancer Clinical
applications of 18F-FDG PET and PET/CT in head and
neck cancer include staging, detection of synchronous 2nd
primaries,aswellasdetectionofresidualorrecurrentdisease
after completion of treatment. Emerging applications are
accurate delineation of the tumor volume for radiotherapy
treatment planning, monitoring treatment, and prediction
in response to targeted therapies. Sentinel node mapping
has emerged as a routine procedure for staging of various
malignancies, because it can determine lymph node status
more accurately. In the review by Vermeeren et al. the
sentinel node procedure and its indications in the head
and neck region are presented. The authors also discuss the
resultsofSPECT/CTforsentinelnodedetectionanddescribe
how a portable gamma camera may enable intraoperative
real-time imaging with improved sentinel node detection.
Advances in molecular biology have oﬀered excit-
ing advances in the treatment of iodine-refractory thy-
roid cancer. Recent novel and promising ﬁndings include
additional abnormalities in key pathways associated with
thyroid tumorigenesis (RET-Ras-BRAF-MEK, RET-beta-
cateinin, TRK-PI3K-AKT, and MDM-p53-PTEN), and gene
expression abnormalities. The review by Pinchot et al.
provides a comprehensive overview of the vital pathways
in Medullary Thyroid Cancer tumorigenesis and focuses on
interesting pathways for which targeted drug therapies are
currently under development. Patients with multiple recur-
rences of well-diﬀerentiated thyroid carcinoma (WDTC)
have signiﬁcantly worse overall survival compared to those
who have ≤1 recurrence of their disease. Holler et al. ana-
lyzed retrospectively 31 patients with multiple recurrences of
WDTC and found that age >45, stage III/IV disease, distant
metastasis, vascular invasion, MACIS score >6, and time
to recurrence of <12 months were found to be signiﬁcant
predictors for mortality in this subgroup.
We hope that this special issue will inspire interests and
new research in the ﬁeld of head and neck cancer. The
development of new targeted therapies the identiﬁcation of
novel predictive and prognostic factors will assist in the
development of personalized medicine so that therapy can
be tailored and optimized in every patient.
Disclosure: PMH has held laboratory research agree-
ments with industry sponsors developing EGFR inhibitors
including Amgen, AstraZeneca, Genentech and ImClone
during the last 5 years.
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